EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Comparative Effectiveness of Clopidogrel vs . Potent P2Y 12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real‐World Cohort Study

Hsing-Yu Hsu, Ke-Wei Chen, Hsing-Fang Lu, Shih-Sheng Chang, Daniel Hsiang-Te Tsai iD, Edward Chia-Cheng Lai iD, Kuan-Cheng Chang iD, Fuu-Jen Tsai

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70373 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Hsing-Yu Hsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Clopidogrel, Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence suggests that cytochrome P450 2C19 (CYP2C19) genotyping may guide clopidogrel therapy after percutaneous coronary intervention (PCI). However, evidence on the effectiveness of clopidogrel and potent P2Y12 inhibitors (ticagrelor or prasugrel) in patients with CYP2C19 normal metabolizer (NM) genotype remain limited.

Methods

This retrospective cohort study utilized nationwide genetic data from China Medical University Hospital, Taiwan. We included patients undergoing PCI with CYP2C19 NM who received dual antiplatelet therapy (DAPT) between 2004 and 2020. The primary outcome was a composite of thrombotic events, including MI, stroke or rehospitalization for stent implantation. Major bleeding events included intracranial and gastrointestinal bleeding requiring hospitalization. Inverse probability of treatment weighting balanced baseline covariates. Hazard ratios and 95% confidence intervals were estimated using Cox regression.

Results

Among patients with CYP2C19 NM with MI ( n = 1825), potent P2Y₁₂ inhibitors were associated with a reduced risk of thrombotic events in patients with MI (HR: 0.76; 95% CI: 0.58–0.98). However, no difference in bleeding risk was observed between treatment groups. Several sensitivity analyses, including as‐treated analysis, supported the robustness of our findings.

Conclusions

Among patients with MI with CYP2C19 NM undergoing percutaneous coronary intervention, the use of potent P2Y₁₂ inhibitors was associated with a reduced risk of thrombotic events at 1 year compared to clopidogrel. These findings indicate genotype‐guided de‐escalation strategies warrant further investigation across diverse clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19ClopidogrelPercutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsThrombosisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedPrasugrel HydrochlorideTicagrelorTaiwanGenotypeMyocardial InfarctionHemorrhageCohort StudiesTreatment OutcomeDual Anti-Platelet TherapyGastrointestinal Hemorrhage

Stichwörter der Autor:innen

CYP2C19 normal metabolizersP2Y₁₂ inhibitorsclopidogrelpercutaneous coronary interventionprecision medicine

Substanzen

Cytochrome P-450 CYP2C19ClopidogrelCYP2C19 protein, humanPurinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsPrasugrel HydrochlorideTicagrelor

Autor:innen und Institutionen

  • Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan.
  • Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • School of Medicine, China Medical University, Taichung, Taiwan.
  • Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
  • Master Program for Digital Health Innovation, China Medical University, Taichung, Taiwan.

ORCID-Profile: Daniel Hsiang-Te Tsai, Edward Chia-Cheng Lai, Kuan-Cheng Chang

Zitieren

APA

Hsu, H. Y., Chen, K. W., Lu, H. F., Chang, S. S., Tsai, D. H., Lai, E. C., Chang, K. C., & Tsai, F. J. (2025). Comparative Effectiveness of Clopidogrel vs . Potent P2Y 12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real‐World Cohort Study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70373

Vancouver

Hsu HY, Chen KW, Lu HF, Chang SS, Tsai DH, Lai EC, et al. Comparative Effectiveness of Clopidogrel vs . Potent P2Y 12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real‐World Cohort Study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70373

BibTeX
@article{Hsu2025,
  author = {Hsu, Hsing-Yu and Chen, Ke-Wei and Lu, Hsing-Fang and Chang, Shih-Sheng and Tsai, Daniel Hsiang-Te and Lai, Edward Chia-Cheng and Chang, Kuan-Cheng and Tsai, Fuu-Jen},
  title = {Comparative Effectiveness of Clopidogrel vs . Potent P2Y 12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real‐World Cohort Study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70373}
}
Kostenlos starten →